The Quiet Leader Who Built a $130B Health Company

Paul Perreault led CSL for a decade, growing it into a $130 billion market cap company and the world's leading manufacturer of plasma derived therapies. He started as a field sales rep, planned to become a priest, and carried one lesson through his entire career: never confuse your job title with who you are.In this conversation Paul talks about the generalist philosophy that shaped his leadership, the capital discipline that made CSL different from every other biotech, the three major acquisitions that defined his tenure including the one that did not play out as expected, what it was like navigating Covid as a company deep in plasma collection and vaccine manufacturing, and when he knew it was time to leave a company before complacency set in.Direct, patient, and completely uninterested in the spotlight.Let's connect: LinkedIn: / sheetal-mehta-prasadOur Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneededTimestamps:0:00 - Teaser: never confuse your job with who you are0:50 - Introduction: Paul Perreault and CSL2:10 - The Detour CEO: what detour means in a career3:54 - The seminary: why the structure forced him to leave6:08 - You can be CEO of the largest company and still take out the trash6:39 - Growing up the second of eight kids and what it taught him7:23 - Starting as a field rep and planning to retire as one8:09 - The value of being a generalist in a world that rewards specialists9:27 - The Wharton simulation: why diverse teams build better businesses12:46 - His father worked at the same company: what he learned from him13:52 - When is the right time to leave? The complacency signal15:33 - Once you hit the peak it is all downhill16:09 - Joining Centeon: the leap from a large company to a small one16:31 - Why the plasma business is completely different from pharma and biotech18:31 - 200 days from collection to product on the market19:19 - Why CSL required extreme capital discipline that pharma never does20:36 - Becoming CEO in 2013 and the decision to accelerate plasma center growth21:08 - What immune deficiency actually looks like for patients24:07 - Growing plasma centers: the demand was always there, the supply was not27:20 - The flu vaccine acquisition: everybody said he was crazy30:57 - They all said I was crazy. Less than five years later: $1B in revenue and 20% EBITDA.32:09 - The gene therapy deal: why he waited until 2020 to enter the space33:46 - Why he went after hemophilia B when everyone else chased hemophilia A35:31 - There is a lot of money in a cure: the economics of the $3.5M treatment36:39 - The scoreboard was never the game plan37:09 - The $11.7B Vifor acquisition: the deal that did not go as expected38:30 - The opportunity was right. Maybe the price was not.42:43 - Nobody from the company had ever visited the plants. He showed up anyway.44:16 - We were not serial acquirers. Three deals in ten years.45:08 - Covid: screaming for a vaccine, then criticizing it when side effects emerged46:42 - The product was not rushed. The funding just moved faster.47:30 - Getting three competitors together to collect convalescent plasma49:09 - Feeling helpless in Switzerland while his teams showed up every day51:10 - Covid was the macro example of something leaders face every single day52:39 - Sustaining mental, physical, business, and family health all at once52:53 - Closing reflections